samedan logo
 
 
 
spacer
home > ebr > autumn 2019 > advancing liquid biopsies
PUBLICATIONS
European Biopharmaceutical Review

Advancing Liquid Biopsies




The rise of liquid biopsies has ushered in many exciting new opportunities, particularly in oncology-focused applications relevant to pharmaceutical scientists engaged in drug discovery and development pipelines. While the term ‘liquid biopsy’ has been applied to circulating tumour cells and other analytes, it is generally associated with the analysis of cell-free DNA (cfDNA) that is shed from solid tumours and derived from peripheral blood.

Before the introduction of liquid biopsies, scientists were usually limited to working with tissue biopsy samples. These required invasive, often painful medical procedures and frequently yielded inevaluable samples. The idea of monitoring patients frequently – such as collecting tumour biopsies at every treatment cycle to gauge treatment response – was unthinkable.

Now, scientists can ask questions that have never been possible before and monitor tumour evolution in near real time. Implementing liquid biopsies, requiring only a simple blood draw from patients, has suddenly made it feasible to gather new information from patients on a regular basis and over long periods of time. Thanks to the next-generation sequencing (NGS) technologies used to analyse these blood samples, liquid biopsy assays can have remarkable sensitivity and specificity while evaluating thousands of potential mutation sites. They can detect not only single nucleotide variants and insertions and deletions (indels), but also more complicated mutations such as gene fusions and copy number variations. Already, this has fundamentally changed how researchers can evaluate treatment response, detect tumour progression with the rise of resistance mutations, and monitor patients longitudinally.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Mark Li serves as President and CEO of Resolution Bioscience. He is a serial investor and entrepreneur who is now focused on applying startup methodologies from the tech industry to develop better medical devices. Earlier in his career, he founded Yahoo! Europe and was responsible for starting and overseeing engineering operations for Yahoo! in 23 countries. Mark also pioneered early desktop publishing in the book, magazine, and multimedia CD-ROM industry while at Ziff-Davis Publishing. He earned his BSc in zoology/ animal biology from the University of California, US.
spacer
Mark Li
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo keeps growing in the first quarter of 2019

Maintaining its accomplished operations from Ataturk and Istanbul airports as "Dual Hub", the global brand of Turkish Cargo continued its strong growth momentum during the first quarter of the year despite the shrinkage of the global air cargo sector.
More info >>

White Papers

Life Cycle of an Analytical Method - a Case Study on the Monocyte Activation Test

Wickham Laboratories Limited

Pyrogens, a heterogeneous group of fever inducing contaminants, are comprised of microbial and non-microbial compounds; e.g. endotoxin (lipopolysaccharide, LPS) produced by Gram-negative bacteria, lipoteichoic acid (LTA) from Gram-positive bacteria, bacterial DNA (CpG-motive), endogenous pyrogens, virus and fungi particles or even fragments of packaging materials, plastic and dust. Contaminat ion wi th pyrogens in pharmaceutical products, biotherapeutics and on medical devices can lead to life threatening fever reactions. To ensure consumer safety, pyrogen testing is mandatory for parenteral products and medical devices.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement